Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
25-10-06	Alzinova gets fast track designation from US FDA	RE
25-10-05	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	2024-09-30
Anders Sandberg COO	Chief Operating Officer	54	2011-08-16
Erik Kullgren DFI	Director of Finance/CFO	57	2024-03-26

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	2015-08-31
Anders Waas BRD	Director/Board Member	69	2017-12-31
Carol Routledge BRD	Director/Board Member	-	2017-12-31

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+12.00%	+25.56%	-53.59%	-75.76%	15.56M
LONZA GROUP AG	+1.07%	-3.49%	-3.25%	+12.87%	46.35B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+408.41%	+629.49%	40.13B
BEONE MEDICINES AG	-0.27%	+4.45%	+9.93%	+66.92%	36.33B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+3.60%	-8.81%	34.6B
CELLTRION, INC.	+3.14%	+1.02%	+3.37%	+38.15%	26.77B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.66B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+31.97%	+143.53%	16.91B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	+0.76%	+8.50%	13.05B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-15.00%	-31.68%	13.05B
Average	+1.40%	+1.64%	+42.91%	+87.02%	24.39B
Weighted average by Cap.	+0.46%	+1.10%	+75.56%	+137.01%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-19 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	SEK 0.8400	+12.00%	3,016,369
26-07-23	SEK 0.7500	+7.45%	2,704,804
26-07-22	SEK 0.6980	+5.76%	5,698,218
26-07-21	SEK 0.6600	+0.15%	1,924,520
26-07-20	SEK 0.6590	-1.49%	1,360,375

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-24 EDT			5-day change	1st Jan Change
0.8400 ^SEK	+12.00%		+25.56%	+1.33%

Market Cap	170M 17.55M 15.41M 14.33M 13.15M 24.71M 1.69B 25.1M 66.5M 831M 65.88M 64.46M 2.87B	P/E 2026 *	-3.11x	P/E 2027 *	-2.21x
Enterprise Value	154M 15.9M 13.96M 12.99M 11.92M 22.39M 1.53B 22.74M 60.25M 753M 59.69M 58.4M 2.6B	EV / Sales 2026 *	4.92x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	+12.00%
1 week	+25.56%
Current month	+69.35%
1 month	+58.49%
3 months	+85.02%
6 months	+8.11%
Current year	+1.33%

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.61	0.84
1 month	0.48	1.61
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.23M 2.84M 2.64M 2.42M 4.55M 311M 4.62M 12.25M 153M 12.13M 11.87M 529M	-
Net income	-3.2M -330K -290K -269K -247K -465K -31.77M -472K -1.25M -15.62M -1.24M -1.21M -54.01M	-50.35M -5.19M -4.56M -4.24M -3.89M -7.31M -500M -7.42M -19.67M -246M -19.49M -19.07M -850M
Net Debt	-16M -1.65M -1.45M -1.35M -1.24M -2.32M -159M -2.36M -6.25M -78.1M -6.19M -6.06M -270M	-19M -1.96M -1.72M -1.6M -1.47M -2.76M -189M -2.8M -7.42M -92.74M -7.35M -7.2M -321M